TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion
Sponsors
Grupo Espanol De Investigacion En Cancer De Mama, Mirati Therapeutics Inc., Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Cancer Trials Ireland, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Conditions
Advanced Non-Small Cell Lung CancerHormone Receptor-Positive and Her2-Negative Breast Cancer with recurrence Score (RS) of 25 or LessNon-Small Cell Lung CancerPatients with 1-3 positive NodesPatients with invasive breast cancer in early stagesmetastatic castration-resistant prostate cancerperitoneal dissemination in stomach cancer patients
Phase 2
A randomized phase II trial of docetaxel or cabazitaxel with or without darolutamide in men with metastatic castration-resistant prostate cancer.
Not yet recruitingCTIS2024-516939-28-00
Target: 245Updated: 2025-12-03
Treatment of peritoneal dissemination in stomach cancer patients with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy; PERISCOPE-2
Active, not recruitingCTIS2023-510159-53-01
Start: 2017-09-28Target: 226Updated: 2025-01-22
Phase 3
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
Active, not recruitingCTIS2023-507263-19-00
Start: 2020-12-23Target: 557Updated: 2025-12-22
SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endrocrine Therapy +/- Chemotheraphy in Patients with 1-3 Positive Nodes Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or less
Active, not recruitingCTIS2024-516801-22-00
Start: 2012-04-26Target: 141Updated: 2025-05-20
A Multicenter, Open-label, Randomized Phase 3 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) vs Investigator Choice of Single-agent Chemotherapy as Third-line Treatment in Subjects with Advanced / Metastatic Non-Small Cell Lung Cancer (NSCLC)
Not yet recruitingCTIS2024-520164-33-00
Target: 80Updated: 2025-09-19